SynthesisFrontiers in oncology2026
Bibliometric analysis of knowledge maps and future trends of TIM-3 in cancer.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study conducted a bibliometric analysis of TIM-3 research in cancer in the past 25 years and expounded on the mainstream countries, institutions, authors, journals, and publications in this field. It intuitively depicts the evolution trajectory and future direction of TIM-3 research in the past 25 years. Materials and methods: The published literature on the role of TIM-3 in cancer research was retrieved from the WoSCC and PubMed databases. Various bibliometric tools (including VOSviewer and CiteSpace) were used to identify the historical features, the evolution of active topics, and emerging trends. Results: A total of 1466 articles were retrieved, with the main contributors including China, the United States, and Japan. The journal with the most published articles was Frontiers in Immunology. Anderson AC is the core author of this research field. The most common keyword is "TIM-3." Furthermore, 37 clinical trial articles in the PubMed database were included. The analysis indicated that the main contributing countries were the United States, China, and Japan, with the United States being the pioneer of TIM-3 clinical research in cancer. Among these authors, Leena Gandhi published the highest number of articles. Keyword analysis indicated that most researchers experimentally validated and analyzed the characteristics of immune cells and biomarkers within the tumor microenvironment to predict clinical responses and mechanisms of resistance in cancer immunotherapy. Conclusion: The findings of this bibliometric study help researchers discover important topics and future research objectives by offering insights into the existing state and trends of TIM-3 in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.